Greg Grunberg, MD

Dr. Grunberg is a Managing Director of Longitude Capital. Prior to joining Longitude Capital in 2012, Dr. Grunberg was a Principal at Rho Ventures and an Engagement Manager at McKinsey & Company. Dr. Grunberg is a board-certified physician in Internal Medicine and completed his residency at Cornell’s New York Presbyterian Hospital. He has maintained a limited clinical practice in Internal Medicine and affiliations with UCSF and Kaiser Permanente. Dr. Grunberg currently serves on the boards of BAROnova, California Cryobank, and Kala Pharmaceuticals. He formerly served on the board of AqueSys (acquired by Allergan) and was a board observer at SARCode Bioscience (acquired by Shire) while at Rho Ventures. Dr. Grunberg holds an M.D. and an M.B.A from Duke University where he was a Fuqua Scholar and an A.B. in Economics and English from Amherst College.